NCT00002403 is a Phase 1 clinical trial of Zintevir in HIV Infections, sponsored by Aronex Pharmaceuticals.

Who is sponsoring NCT00002403?

NCT00002403 is sponsored by Aronex Pharmaceuticals.

What drugs are being tested in NCT00002403?

Interventions in NCT00002403: Zintevir.

What condition does NCT00002403 study?

NCT00002403 studies HIV Infections.

Is NCT00002403 still recruiting?

NCT00002403 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00002403

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I/II Multiple Dose Study to Evaluate the Safety, Pharmacokinetic Profile and Virologic/Immunologic Activity of Zintevir (AR177) in HIV-1 Patients

Completed Phase 1 Last updated 23 June 2005

What this trial tests

Phase 1 trial testing Zintevir in HIV Infections in 12 participants. Completed.

Quick facts

Lead sponsor	Aronex Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	12
Sites	1 location across United States

Drugs / interventions tested

Zintevir — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Aronex Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to asymptomatic (no symptoms) HIV-infected patients. Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the protein integrase to infect a cell. Integrase inhibitors block integrase and may stop replication of HIV.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

G-quadruplex-based aptamers against protein targets in therapy and diagnostics.
Platella C, Riccardi C, Montesarchio D, Roviello GN, et al · · 2017 · cited 111× · PMID 27865995 · DOI 10.1016/j.bbagen.2016.11.027

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002403 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aronex Pharmaceuticals
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing